• Explore /
  • Poster
  • / A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).

A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).

Abstract Poster

Authors

null

Anup Kasi

University of Kansas Cancer Center, Kansas City, KS

Anup Kasi , Milind A. Phadnis , Raed Moh'd Taiseer Al-Rajabi , Joaquina Celebre Baranda , Haoran Li , Erin Carroll , Cathey Belcher , Shannon Bradbury , Zachary Collins , Weijing Sun

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05915351

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS719)

DOI

10.1200/JCO.2024.42.3_suppl.TPS719

Abstract #

TPS719

Poster Bd #

Q8

Abstract Disclosures

Similar Posters

First Author: Justine Yang Bruce

First Author: Dong-Sheng Zhang

First Author: Christopher Jakubowski

First Author: Patricia LoRusso